The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, ...

Pancreatic cancer is one of the most aggressive cancers and has one of the lowest survival rates—only 10% after five years.

A laboratory on Long Island has found a breakthrough in the fight against pancreatic cancer that can “intercept” its spread.

KRAS G12C inhibitors mark a breakthrough in oncology, but resistance is driving the need for smarter preclinical models and ...

City of Hope researchers demonstrate proof of concept for a novel targeted therapy for pancreatic cancer, exploiting transcription-replication conflicts to combat treatment resistance.

Researchers have identified a new molecular target for treating pancreatic cancer. Scientists focused on transcription-replication conflicts (TRCs), which occur when the mechanisms responsible for ...

Researchers at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S.

A review paper published last year in European Journal of Medicinal Chemistry characterized Myc as the “oncogene from ...

Johns Hopkins Medicine scientists say they have found a pattern of so-called epigenetic “marks” in a transition state between normal and pancreatic cancer cells in mice, and that the normal cells may ...

Reference: Vinaixa J, Martínez-Bosch N, Gibert J, et al. Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells. PNAS. 2025;122(14):e2424051122. doi: ...

A new study focused on transcription-replication conflicts, which occur when mechanisms responsible for gene expression and genome duplication collide.

Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells. Proc Natl Acad Sci U S A. 2025 Apr 8;122(14):e2424051122. doi: 10.1073/pnas.2424051122. Epub 2025 Apr 2.